Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFINITY: Custirsen + Cabazitaxel in mCRPC
NCT01578655Phase 3Completed
- Sponsor
- Achieve Life Sciences
- Start
- Aug 2012
- Primary completion
- Jul 2016
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 8
01
Overview
A Phase 3 trial of custirsen in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Achieve Life Sciences. Started Aug 2012; status: completed.
02
Drugs
custirsen
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01578655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01578655.